A polymerase chain reaction (PCR)-based assay of antenatal maternal serum can determine fetal Rh status in over 99% of cases with 100% accuracy, according to a recently published French study involving 285 pregnant women. Researchers were able to determine fetal RhD status in all but two cases.
A polymerase chain reaction (PCR)-based assay of antenatal maternal serum can determine fetal Rh status in over 99% of cases with 100% accuracy, according to a recently published French study involving 285 pregnant women. Researchers were able to determine fetal RhD status in all but two cases. (In those two cases, the RhD-negative phenotype of the mother was not the result of a complete RHD gene deletion.) No false-positive or false-negative results occurred; all sera from women carrying an RhD-positive fetus had positive results for RHD gene detection, and all sera from women carrying an RhD-negative fetus had negative results.
The authors concluded that such a test could be offered to all RhD-negative pregnant women to avoid unnecessary use of Rh immune globulin. In addition, such an assay could replace amniocentesis as a means for determining whether a fetus is at risk for hemolytic disease.
Gautier E, Benachi A, Giovangrandi Y, et al. Fetal RhD genotyping by maternal serum analysis: a two-year experience. Am J Obstet Gynecol. 2005;192:666-669.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More